MeSH D054078 - mevalonate kinase deficiency
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Canakinumab | Ilaris | 2009-06-17 | $1,206 M | Q2/21-Q2/24 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
0%0/1
Phase 3
100%1/1
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use